


#15/1/02
01-15-03



Electronic Information Disclosure Statement

Multipotent neural stem cells from peripheral tissues and uses thereof.






Application: 
09/670049
Confirmation: 4083
Applicant(s): Freda Miller
Docket Number: CIBT-P03-120
Group Art Unit:
Examiner: Murphy, Joseph F.
search string: (5338839 or 5753506 or 5912175 or 6001654 or 6093531).pn.

RECEIVED
DEC 12 2002
TC 1700
RECEIVED
DEC 13 2002
TECH CENTER 1600/2900

12/11/2002 MDAFTE1 00000015 181945 09670049
01 FC:1806 180.00 CH

US Patent Documents


Note: Applicant is not required to submit a paper copy of cited US Patent Documents

init	Citation No.	Patent Number	Date	Bar Code	Patentee	Class	Subclass
/	P01	5338839	1994-08-16		McKay et al.		
/	P02	5753506	1998-05-19		Johe		
/	P03	5912175	1999-06-15		Wille		
/	P04	6001654	1999-12-14		Anderson et al.		
/	P05	6093531	2000-07-25		Bjornson et al.		

Remarks


(Remarks are not for responding to an office action.)

Pursuant to 37 CFR 1.56, the attention of the Patent and Trademark Office is hereby directed to the

 1-12-07
APP_ID=09670049

list of U.S. Patents attached to this online submission. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom. While the information and references disclosed in this Information Disclosure Statement may be "material" pursuant to 37 CFR 1.56, it is not intended to constitute an admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such. In accordance with 37 CFR 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR 1.56(a) exists. Applicants further reserve the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should one or more of the documents be applied against the claims of the present application. This Information Disclosure Statement is filed more than three months after the U.S. filing date, OR more than three months after the date of entry of the national stage of a PCT application, AND after the mailing date of the first Office Action on the merits, whichever occurs first, but before the mailing date of a Final Rejection or Notice of Allowance. Please charge our Deposit Account No. 18-1945 in the amount of \$180.00 covering the fee set forth in 37 CFR 1.17(p). The Commissioner is hereby authorized to charge any deficiency in the fees filed, asserted to be filed or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Deposit Account No. 18-1945, under Order No. ASZD-P01-468.

Signature

Examiner Name	Date
	1-12-07